• SnoreStop® for Pets Tablets

SnoreStop® for Pets Tablets

SKU: 006
$9.99

About The Product


Ingredients


Reviews

Pet snoring is a result of an obstruction in one or more airways. Our gentle formula is free from any sedative or stimulating effects. It helps open and clear the airways for better breathing. SnoreStop for Pets is a natural solution for your pet's snoring problem and your guarantee of a good night's sleep! 

  • Non-habit forming
  • Non-drowsy
  • Non-sedative
  • No stimulants

Directions:

One tablet at bedtime. Place directly into a treat or crush a tablet inside a water dish, fill with water. You may double the dosage at your discretion.
For best results, we recommend repeated use of the product for 3 to 5 consecutive nights. 

*Individual results may vary.

 

 

    Active Ingredients:
    • Nux vomica 4X,6X: helps open constricted pharynx
    • Belladonna 6X: helps decongest enlarged tonsils 
    • Ephedra Vulgaris 6X: helps relieve congestion 
    • Hydrastis Canadensis 6X: helps decongest swollen tongue 
    • Kali Bichromicum 6X: helps relieve stuffy nose 
    • Teucrium marum 6X: helps open air passages 
    • Histaminum 12X: natural antihistamine

    Inactive ingredients: Lactose, Cellulose, Dextrose, Croscamellose sodium, Magnesium stearate (in each 300 mg tablet).

     

    SnoreStop for Pets tablets is prepared in accordance with the Homeopathic Pharmacopoeia of the United States (HPUS). All ingredients are recognized as an official collection of accepted drug ingredients by the Federal Food, Drug and Cosmetic Act and are manufactured in FDA-approved laboratories. Each natural ingredient comes either from plant, mineral or protein sources and is present only in harmless microscopic amounts in each dose. None of our ingredients contain any alkaloids, ephedrine or pseudo - ephedrine. SnoreStop is a natural homeopathic over-the-counter medicine regulated by the FDA.

    Dilution Scale: 6X is equal to one part per million.

    Claims follow requirement in CPG 400.400 and GLP of Sections 502 & 503 of the FDCA (“The Act”) and Part 201 Title 21 of the CFR to include Principle Display Panel of OTC Drug Labeling under 21 CFR 201.62. Uses and claims are taken from various authorized Materia Medica for references. They have not been reviewed by the Federal Drug and Administration.